Epilepsy and seizures are more frequent in the elderly population than in any other age group. The number of individuals older than 65 is constantly increasing, and dementia is a process that predominantly affects this age group. Several studies have shown that dementia is an important risk factor for developing seizures and epilepsy. Seizure semiology in the elderly demented might differ from that of younger age groups and diagnosis can be complicated further by the variety of other causes of transient changes of alertness and behavior that affects these patients. The pharmacokinetic changes of antiepileptic drugs in the elderly make this group a major therapeutic challenge. Side effects and drug interactions play a major role in the choice of antiepileptic agents. This review intends to summarize the existing data to see whether this can help guide the clinician in the treatment and management of epilepsy in the elderly patient with dementia. Nonpharmacologic therapeutic options are also briefly considered.
Olshansky SJ , Carnes BA, Cassel CKThe aging of the human species. Sci Am. 1993;268:46-52.
2.
Hauser WA, Annegers JF, Kurland LTIncidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984 . Epilepsia. 1993;34:453-468.
3.
Romanelli MF , Morris JC, Ashkin K., Coben LAAdvanced Alzheimer’s disease is a risk factor for late-onset seizures. Arch Neurol. 1990;47:847-850.
4.
Aldenkamp AP , De Krom M., Reijs R.Newer antiepileptic drugs and cognitive issues . Epilepsia. 2003;44(suppl 4): 21-29.
5.
Forstl H., Burns A., Levy R., Cairns N., Luthert P., Lantos P.Neurologic signs in Alzheimer’s disease. Results of a prospective clinical and neuropathologic study. Arch Neurol. 1992 ;49:1038-1042.
6.
Mendez M., Lim G.Seizures in elderly patients with dementia: epidemiology and management [review] . Drugs Aging. 2003;20:791-803.
7.
Hesdorffer DC , Hauser WA, Annegers JF, Kokmen E., Rocca WADementia and adult-onset unprovoked seizures . Neurology. 1996;46:727-730.
8.
DeLorenzo RJClinical and epidemiological study of status epilepticus in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly. Boston, MA: Butterworth-Heineman;1997:191-205.
9.
Tinuper P., Provini F., Marini C., et al. Partial epilepsy of long duration: changing semiology with age . Epilepsia. 1996;37:162-164.
10.
Sheth RD, Drazkowski JF, Sirven JI, Gidal BE, Hermann BPProtracted ictal confusion in elderly patients. Arch Neurol . 2006;63:529-532.
11.
Ramsay RE, Rowan AJ, Pryor FMSpecial considerations in treating the elderly patient with epilepsy. Neurology. 2004;62 (suppl 2):24S-29S.
12.
Hiyoshi T., Yagi K.Epilepsy in the elderly. Epilepsia. 2000;41(suppl 9):31-35.
13.
LaRoche SM, Helmers SLEpilepsy in the elderly [review]. Neurologist. 2003;9:241-249.
14.
Pillai J., Sperling MR. Interictal EEG and the diagnosis of epilepsy. Epilepsia. 2006;47(suppl 1):14-22.
15.
Drury I., Beydoun A.Interictal epileptiform activity in elderly patients with epilepsy. Electroencephalogr Clin Neurophysiol. 1998;106:369-373.
16.
Keranen T., Rainesalo S., Peltola J.The usefulness of video-EEG monitoring in elderly patients with seizure disorders . Seizure. 2002;11:269-272.
17.
Drury I., Selwa LM, Schuh LA, et al. Value of inpatient diagnostic CCTV-EEG monitoring in the elderly . Epilepsia. 1999;40:1100-1102.
18.
Stephen LJ, Kelly K., Mohanraj R., Brodie MJPharmaco- logical outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav. 2006;8:434-437.
19.
Cameron H., Macphee GJAnticonvulsant therapy in the elderly-a need for placebo controlled trials . Epilepsy Res. 1995;21:149-157.
20.
Luhdorf K., Jensen LK, Plesner AMEpilepsy in the elderly: life expectancy and causes of death. Acta Neurol Scand. 1987;76:183-190.
21.
Bowen JD, Larson EBDrug-induced cognitive impairment. Defining the problem and finding solutions . Drugs Aging. 1993;3:349-357.
22.
Pack AM, Morrell MJEpilepsy and bone health in adults. Epilepsy Behav. 2004;5(suppl 2):24S-29S.
23.
Apeland T., Mansoor MA, Strandjord RE, Kristensen O.Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand. 2000;101:217-223.
24.
Schmucker DLLiver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18: 837-851.
25.
Temellini A. , Giuliani L., Pacifici GMInterindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. Br J Clin Pharmacol. 1991;31:661-664.
26.
Farinati F. , Formentini S., Della Libera G., et al. Changes in parietal and mucous cell mass in the gastric mucosa of normal subjects with age: a morphometric study . Gerontology. 1993;39:146-151.
27.
Williams L. , Lowenthal DTDrug therapy in the elderly. South Med J. 1992;85:127-131.
28.
Feely J., Coakley D.Altered pharmacodynamics in the elderly. Clin Geriatr Med . 1990;6:269-283.
29.
Ensrud KE, Walczak TS, Blackwell T., Ensrud ER, Bowman PJ, Stone KLAntiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004;62:2051-2057.
30.
Lahr MBHyponatremia during carbamazepine therapy. Clin Pharmacol Ther. 1985;37:693-696.
31.
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64: 1868-1873.
32.
Jamora D., Lim SH, Pan A., Tan L., Tan EKValproateinduced parkinsonism in epilepsy patients. Mov Disord . 2007;22:130-133.
33.
Messina S., Battino D., Croci D., Mamoli D., Ratti S., Perucca E.Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsia. 2005;46:372-377.
34.
Hawkins JW, Tinklenberg JR, Sheikh JI, Peyser CE, Yesavage JAA retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry. 2000; 8:221-225.
35.
Raudino F., Mascalzi MG, Zagami A.Gabapentin and behavioral disorders in severe Alzheimer disease. J Clin Psychopharmacol. 2004;24:459-460.
36.
Groselj J., Guerrini R., Van Oene J., et al; TOP-INT-51 Investigators’ Group. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand. 2005;112:144-150.
37.
Kanner AM, Wuu J., Faught E., et al; The PADS Investigators. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events . Epilepsy Behav. 2003;4:548-552.
38.
Alsaadi TM, Koopmans S., Apperson M., Farias S.Levetiracetam monotherapy for elderly patients with epilepsy. Seizure. 2004;13:58-60.
39.
Patsalos PNClinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707-724.
40.
White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003;61:1218-1221.
41.
Brodie MJ, Overstall PW, Giorgi L.Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK lamotrigine elderly study group. Epilepsy Res. 1999;37:81-87.
42.
Hirsch LJ, Weintraub DB, Buchsbaum R., et al. Predictors of lamotrigine-associated rash. Epilepsia. 2006;47:318-322.
43.
May TW, Korn-Merker E., Rambeck B.Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet . 2003;42:1023-1042.
44.
Kutluay E., McCague K., D’Souza J., Beydoun A.Safety and tolerability of oxcarbazepine in elderly patients with epilepsy . Epilepsy Behav. 2003;4:175-180.
45.
Ben-Menachem E.Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(suppl 6): 13-18.
46.
Hamandi K., Sander JWPregabalin: a new antiepileptic drug for refractory epilepsy. Seizure. 2006;15:73-78.
47.
Grivas A., Schramm J., Kral T., et al. Surgical treatment for refractory temporal lobe epilepsy in the elderly: seizure outcome and neuropsychological sequels compared with a younger cohort. Epilepsia. 2006;47: 1364-1372.
48.
Sirven JI, Sperling M., Naritoku D., et al. Vagus nerve stimulation therapy for epilepsy in older adults . Neurology. 2000;54:1179-1182.
49.
Merrill CA, Jonsson MA, Minthon L., et al. Vagus nerve stimulation in patients with Alzheimer’s disease: additional follow-up results of a pilot study through 1 year. J Clin Psychiatry. 2006;67:1171-1178.
